Development, characterization and antimalarial efficacy of dihydroartemisinin loaded solid lipid nanoparticles

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 3, 2016, Pages 801-809

  Omwoyo, Wesley N ^a,b   Melariri, Paula ^c   Gathirwa, Jeremiah W ^d,e   Oloo, Florence ^e,f   Mahanga, Geoffrey M ^b   Kalombo, Lonji ^c   Ogutu, Bernhards ^d,e   Swai, Hulda ^c  

^a MAASAI MARA UNIVERSITY   (Kenya)

^b JARAMOGI OGINGA ODINGA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Kenya)

^c DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e STRATHMORE UNIVERSITY   (Kenya)

^f TECHNICAL UNIVERSITY OF KENYA   (Kenya)

Author keywords

Dihydroartemisinin; Nanomedicine drug delivery; Solid lipid nanoparticles

Indexed keywords

MEDICAL NANOTECHNOLOGY; PARTICLE SIZE;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL EFFICACIES; DIHYDROARTEMISININ; PARTICLE CHARACTERISTICS; PHARMACOKINETIC PROFILES; POLYDISPERSITY INDICES; SOLID LIPID NANOPARTICLE (SLN); SOLID LIPID NANOPARTICLES;

NANOPARTICLES;

DIHYDROARTEMISININ; SOLID LIPID NANOPARTICLE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG CARRIER; LIPID; NANOPARTICLE;

ARTICLE; DRUG ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; IC50; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NANOENCAPSULATION; NANOMEDICINE; OUTCOME ASSESSMENT; PARTICLE SIZE; SURFACE CHARGE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; CHEMISTRY; DRUG EFFECTS; HUMAN; MALARIA; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; ULTRASTRUCTURE;

ANTIMALARIALS; ARTEMISININS; DRUG CARRIERS; HUMANS; LIPIDS; MALARIA; NANOPARTICLES; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM;

EID: 84959441611     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.11.017     Document Type: Article

References (45)

1. Daneshvar C., Davis T.M.E., Cox-Singh J., Rafa'ee M.Z., Zakaria S.K., Divis P.C.S., et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect Dis 2009, 49:852-860. 10.1086/605439.
2. Hall B.F., Fauci A.S. Malaria control, elimination, and eradication: the role of the evolving biomedical research agenda. J Infect Dis 2009, 200:1639-1643. 10.1086/646611.
3. Gallup J.L., Sachs J.D. The economic burden of malaria. Am J Trop Med Hyg 2001, 64:85-96. [doi:11425181].
4. Garner P. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004, 363:9-17. 10.1016/S0140-6736(03)15162-8.
5. Wang D., Li H., Gu J., Guo T., Yang S., Guo Z., et al. Ternary system of dihydroartemisinin with hydroxypropyl-β-cyclodextrin and lecithin: simultaneous enhancement of drug solubility and stability in aqueous solutions. J Pharm Biomed Anal 2013, 83:141-148. 10.1016/j.jpba.2013.05.001.
6. Suputtamongkol Y., Newton P.N., Angus B., Teja-Isavadharm P., Keeratithakul D., Rasameesoraj M., et al. A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. Br J Clin Pharmacol 2001, 52:655-661. 10.1046/j.1365-2125.2001.01458.x.
7. Batty K.T., Ilett K.F., Davis T.M.E. Protein binding and α:β anomer ratio of dihydroartemisinin in vivo. Br J Clin Pharmacol 2004, 57:529-533. 10.1046/j.1365-2125.2003.02045.x.
8. Binh T.Q., Ilett K.F., Batty K.T., Davis T.M.E., Hung N.C., Powell S.M., et al. Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Br J Clin Pharmacol 2001, 51:541-546. 10.1046/j.1365-2125.2001.01395.x.
9. Parveen S., Sahoo S.K. Polymeric nanoparticles for cancer therapy. J Drug Target 2008, 16:108-123. 10.1080/10611860701794353.
10. Singh K.K., Vingkar S.K. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharm 2008, 347:136-143. 10.1016/j.ijpharm.2007.06.035.
11. Tayade N.G., Nagarsenker M.S. Development and evaluation of artemether parenteral microemulsion. Indian J Pharm Sci 2010, 72:637-640. 10.4103/0250-474X.78536.
12. Joshi M., Pathak S., Sharma S., Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int J Pharm 2008, 364:119-126. 10.1016/j.ijpharm.2008.07.032.
13. Haas S.E., Bettoni C.C., de Oliveira L.K., Guterres S.S., Dalla Costa T. Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo. Int J Antimicrob Agents 2009, 34:156-161. 10.1016/j.ijantimicag.2009.02.024.
14. Leite E.A., Grabe-Guimarães A., Guimarães H.N., Machado-Coelho G.L.L., Barratt G., Mosqueira V.C.F. Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices. Life Sci 2007, 80:1327-1334. 10.1016/j.lfs.2006.12.019.
15. Ansari M.T., Sunderland V.B. Solid dispersions of dihydroartemisinin in polyvinylpyrrolidone. Arch Pharm Res 2008, 31:390-398. 10.1007/s12272-001-1169-6.
16. Chingunpitak J., Puttipipatkhachorn S., Chavalitshewinkoon-Petmitr P., Tozuka Y., Moribe K., Yamamoto K. Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method. Drug Dev Ind Pharm 2008, 34:314-322. 10.1080/03639040701662388.
17. Chingunpitak J., Puttipipatkhachorn S., Tozuka Y., Moribe K., Yamamoto K. Micronization of dihydroartemisinin by rapid expansion of supercritical solutions. Drug Dev Ind Pharm 2008, 34:609-617. 10.1080/03639040701833682.
18. Illapakurthy A.C., Sabnis Y.A., Avery B.A., Avery M.A., Wyandt C.M. Interaction of artemisinin and its related compounds with hydroxypropyl-beta-cyclodextrin in solution state: experimental and molecular-modeling studies. J Pharm Sci 2003, 92:649-655. 10.1002/jps.10319.
19. Ansari M.T., Batty K.T., Iqbal I., Sunderland V.B. Improving the solubility and bioavailability of dihydroartemisinin by solid dispersions and inclusion complexes. Arch Pharm Res 2011, 34(5):757-765. 10.1007/s12272-011-0509-1.
20. Narang A.S., Srivastava A.K. Evaluation of solid dispersions of Clofazimine. Drug Dev Ind Pharm 2002, 28:1001-1013. 10.1081/DDC-120006431.
21. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001, 47:165-196. 10.1016/S0169-409X(01)00105-3.
22. Muller R.H., Keck C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004, 113:151-170. 10.1016/j.jbiotec.2004.06.007.
23. Demirel M., Yazan Y., Müller R.H., Kiliç F., Bozan B. Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul 2006, 18:359-371. 10.1080/02652040010018119.
24. Göppert T.M., Müller R.H. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm 2005, 302:172-186. 10.1016/j.ijpharm.2005.06.025.
25. Omwoyo W., Ogutu B., Oloo F., Swai H., Kalombo L., Melariri P., et al. Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles. Int J Nanomedicine 2014, 3865. 10.2147/IJN.S62630.
26. Sreevidya T.V., Narayana B. Spectrophotometric determination of artemisinin and dihydroartemisinin. Indian J Chem Technol 2008, 15(January):59-62.
27. zur Mühlen A., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998, 45:149-155. 10.1016/S0939-6411(97)00150-1.
28. Moll K., Ljungström I., Perlmann H., Scherf A., Wahlgren M. Methods in malaria research. Evaluation 2008, 1-3:17-21.
29. Desjardins R.E., Canfield C.J., Haynes J.D., Chulay J.D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 1979, 16:710-718. 10.1128/AAC.16.6.710.
30. Tona L., Mesia K., Ngimbi N.P., Chrimwami B., Okond'ahoka Cimanga K., de Bruyne T., et al. In-vivo antimalarial activity of Cassia occidentalis, Morinda morindoides and Phyllanthus niruri. Ann Trop Med Parasitol 2001, 95:47-57. 10.1080/000349800200359.
31. Surolia R., Pachauri M., Ghosh P.C. Preparation and characterization of monensin loaded PLGA nanoparticles: in vitro anti-malarial activity against Plasmodium falciparum. J Biomed Nanotechnol 2012, 8:172-181. 10.1166/jbn.2012.1366.
32. Kouchak M., Avadi M., Abbaspour M., Jahangiri A., Boldaji S.K. Effect of different molecular weights of chitosan on preparation and characterization of insulin loaded nanoparticles by ion gelation method. Int J Drug Dev Res 2012, 4(2):272-277.
33. Mulla J.S., Khazi I.M. Influence of process variables on particle sizes of solid lipid nanoparticles. Indian J Nov Drug Deliv 2009, 1:47-49.
34. Müller R.H., Mehnert W., Lucks J.-S., Schwarz C., Zur Mühlen A., Meyhers H., et al. Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995, 41:62-69.
35. Gadhave A. Determination of hydrophilic-lipophilic balance value 2014, 3(4):573-575.
36. Schmidts T., Dobler D., Nissing C., Runkel F. Influence of hydrophilic surfactants on the properties of multiple W/O/W emulsions. J Colloid Interface Sci 2009, 338(1):184-192. 10.1016/j.jcis.2009.06.033.
37. Griffin W.C. Calculation of HLB values of non-ionic surfactants. J Soc Cosmet Chem 1954, 5(4):249-256.
38. De Rosa G., Iommelli R., La Rotonda M.I., Miro A., Quaglia F. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres. J Control Release 2000, 69:283-295. 10.1016/S0168-3659(00)00315-1.
39. Sah H. Microencapsulation techniques using ethyl acetate as a dispersed solvent: effects of its extraction rate on the characteristics of PLGA microspheres. J Control Release 1997, 47:233-245. 10.1016/S0168-3659(97)01647-7.
40. Rojas J., Pinto-Alphandary H., Leo E., Pecquet S., Couvreur P., Fattal E. Optimization of the encapsulation and release of beta-lactoglobulin entrapped poly(DL-lactide-co-glycolide) microspheres. International Journal of Pharmaceutics 1999, vol 183:67-71. 10.1016/S0378-5173(99)00046-0.
41. Garti N., Aserin A. Double emulsions stabilized by macromolecular surfactants. Adv Colloid Interface Sci 1996, 65:37-69. 10.1016/0001-8686(95)00289-8.
42. Innings F., Fuchs L., Trägårdh C. Theoretical and experimental analyses of drop deformation and break-up in a scale model of a high-pressure homogenizer. J Food Eng 2011, 103:21-28. 10.1016/j.jfoodeng.2010.09.016.
43. Zhang X., Liu J., Qiao H., Liu H., Ni J., Zhang W., et al. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 2010, 197:120-128. 10.1016/j.powtec.2009.09.004.
44. Davis T.M.E., Karunajeewa H.A., Ilett K.F. Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust 2005, 182(4):181-185. [doi:dav10876_fm [pii]].
45. White N.J. Artemisinin resistance-the clock is ticking. Lancet 2010, 376(9758):2051-2052. 10.1016/S0140-6736(10)61963-0.